Your browser doesn't support javascript.
loading
Effect of MS14® on physical activity of multiple sclerosis patients: A randomized triple-blind placebo-controlled clinical trial.
Rezaeizadeh, Hossein; Gharegozli, Kourosh; Nabavi, Seyed Masood; Shayegannejad, Vahid; Ghaffarpoor, Majid; Daneshfard, Babak; Cordato, Dennis; Naseri, Mohsen.
Afiliação
  • Rezaeizadeh H; Department of Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Gharegozli K; Department of Neurology, Shahid Beheshti University of Medical Science, Tehran, Iran.
  • Nabavi SM; Center for Neuroscience and Cognition, Royan Institute, Tehran, Iran.
  • Shayegannejad V; Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Ghaffarpoor M; Department of Neurology, Imam Khomeini Hospital, Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.
  • Daneshfard B; Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran; Persian Medicine Network (PMN), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
  • Cordato D; Ingham Institute for Applied Medical Research, 1 Campbell St, Liverpool, NSW, Australia; Department of Neurophysiology, Liverpool Hospital, NSW, Australia.
  • Naseri M; Traditional Medicine Clinical Trial Research Center, Shahed University, Tehran, Iran. Electronic address: naseri@shahed.ac.ir.
Mult Scler Relat Disord ; 69: 104467, 2023 Jan.
Article em En | MEDLINE | ID: mdl-36529067
INTRODUCTION: Multiple Sclerosis (MS) is a neurological disorder with an increasing global prevalence and severe complications. MS14® is a Persian-medicine-derived natural product with herbal and marine origin which has shown beneficial effects in the management of MS complications. In this study, its effect on physical activity of MS patients was investigated. METHODS: A triple-blind placebo-controlled clinical trial was conducted. Participants used either MS14 capsule or placebo 3 times a day for 3 weeks. At baseline and end of the study, physical activity indices were assessed using international physical activity questionnaire (IPAQ). Secondary outcome measures were Fatigue Severity Scale (FSS), timed 10 m walk, Ashworth scale, and Timed Get up and Go. RESULTS: A total number of 80 MS patients completed the study. At the end of study, improvement of general physical activity (p-value=0.047) and Timed 10 m walk index (p-value=0.003) in the MS14 group was significant when compared to placebo. No serious adverse effects were observed in this study. CONCLUSION: Considering the improvement of some physical activity indices, MS14® is seems to be a safe natural product which could be considered as a supplementary treatment in MS patients. Future larger trials are suggested to further evaluate its efficacy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article